CN Mobile Logo


Renal Cell Carcinoma

Study Validates Prognostic Value of mTOR Pathway Markers in RCC

An external validation study has confirmed that biomarkers of the mTOR pathway have prognostic value in patients with clear cell renal cell carcinoma.

Renal Cell Carcinoma

The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.

A 42-year-old man presented with increasing right hip pain that limited his ability to walk. Magnetic resonance imaging (MRI) revealed a right lytic acetabular lesion. Further work-up included a computed tomography (CT) scan, which revealed an 8-cm left kidney tumor.

The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).

A new study suggests that certain mutagens formed during the cooking of meat are linked to a risk of renal cell carcinoma (RCC).

Patients with renal cell carcinoma whose disease progressed after previous VEGF therapy saw increased delays in disease progression when treated with lenvatinib.

Follow-up of patients with resected non-metastatic RCC should be based on a combination of risk factors for disease recurrence and risk for non-RCC death.

Older patients taking the oral TKIs sorafenib and sunitinib for RCC had a significantly increased risk for cardiovascular events, particularly stroke.


Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.